alexa Nanomedicines can Offer Improved Therapeutic Efficacy through Various Parenteral Routes of Administration | Open Access Journals
ISSN: 2157-7439
Journal of Nanomedicine & Nanotechnology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Nanomedicines can Offer Improved Therapeutic Efficacy through Various Parenteral Routes of Administration

Balabathula P*

Plough Center for Sterile Drug Delivery Systems, University of Tennessee Health Science Center, Memphis, Tennessee, USA

*Corresponding Author:
Balabathula P
Plough Center for Sterile Drug Delivery Systems
University of Tennessee Health Science Center
Memphis, Tennessee, USA
Tel: 001-901-448-2349
E-mail: [email protected]

Received Date: February 25, 2016; Accepted Date: February 26, 2016; Published Date: February 29, 2016

Citation: Balabathula P (2016) Nanomedicines can Offer Improved Therapeutic Efficacy through Various Parenteral Routes of Administration. J Nanomed Nanotechnol 7:e136. doi: 10.4172/2157-7439.1000e136

Copyright: © 2016 Balabathula P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Nanomedicine & Nanotechnology


For life threatening diseases such as infections, the standard drug treatment strategy is to get as much antimicrobial drug as possible to the pathogen as fast as possible to obtain an effective pathogen kill rate [1]. Therefore the route of drug administration is often an injectable true solution because oral administration is often variable in sick patients or physical chemical properties of drug product simply to not allow acceptable bioavailability [2,3]. In critical patients, intravenous administration with an initial bolus dose followed by an infusion to maintain killing concentrations is often the norm [4]. The assumption of this approach is that if sufficient concentrations of the drug are maintained in the blood stream enough of the antimicrobial agent is being “pushed” to the infection site to produce an adequate kill rate.

In contrast, particulate nanomedicines are designed to overcome specific problems in drug delivery. For example, amphotericin B solution has significant renal toxicity and administration problems [5]. Most toxicities are dose related. If killing effectiveness can be raised, the total dose administered can be cut, hopefully avoiding or ameliorating some of the toxicity. In previous studies from our laboratories with highly toxic anticancer agents, formulating the drug into a nanomedicine increased killing efficiency and allowed for a 20%-30% reduction in dose as compared to the non nanomedicine formulations [6]. Several properties contribute to this effect. First, with nanomedicines the dosage form can be targeted to the site of action either passively or actively (or both simultaneously) so that the drug substance is not diluted throughout the body to tissues that do not need the drug [7,8]. For nanomedicines, the blood concentration may not be indicative of the concentration needed for treatment. Rather the drug substance concentration at the intended site is more important. Second, nanomedicines can be optimized so the drug has an extended release profile locally over several days. Third, a diagnostic agent in the nanomedicine particles should allow for a more accurate diagnosis as to the spread of the infection [9]. Hopefully, monitoring of subsequent doses will also allow serial image monitoring of the recovery process. This should allow the attending physicians to better monitor and change dosing regimens thereby producing a more controlled therapeutic response. Fourth, nanomedicine particulates often avoid molecule focused active transport body systems that eliminate drugs in true solution from the body [8,10]. Drug resistance by this mechanism is a fairly common problem with some critical drugs and is not easily overcome. However, most drug exotransporters work on molecular drugs in true solution, not on significantly larger particulate nanomedicines. Nanomedicine particles are considered to be too large for molecular transporters.

With colloidal nanomedicines, size and surface charge matters. Usually internal nanomedicines for parenteral use are in the range of 200 nm or smaller [7,10]. As size decreases effectiveness can increase. Part of this is due to vascular permeability, Biological barriers such as vasculature become much more porous when inflammation is present. This allows small nanomedicine particles to pass onto tissues and have significant penetration to the infection site. This allows for potential intravenous, intramuscular and subcutaneous routes of administration. Since diseases like invasive fungal infections include infections of the CNS and lungs, the delivery system properties are important. With fungal pneumonias it may be possible to administer nanomedicine particles by nebulization both as a nontargeted and target product. Concurrent intravenous administration may also be warranted.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 7977
  • [From(publication date):
    February-2016 - Sep 26, 2017]
  • Breakdown by view type
  • HTML page views : 7906
  • PDF downloads :71

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version